

## **StemRIM Announces Patent Registration (Japan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, and Disseverance Osteochondritis**

**Osaka, Japan, February 15, 2024** – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that a patent has been registered in Japan for the application related to the novel treatment of traumatic cartilage deficiency syndrome, osteoarthritis, and disseverance osteochondritis utilizing the peptide drug developed from the “Regeneration-Inducing Medicine™” development candidate Redasemtide (HMGB1 fragment peptide).

Title of Invention : Therapeutic medication for cartilage disorder  
Region : Japan  
Application No. : 2020-552636  
Registration No. : To be determined  
Applicant : StemRIM, Osaka University

This patent is intended to expand the indications for Redasemtide, which is currently under development, and we believe that the granting of this patent will ensure the possibility of developing a drug for traumatic cartilage deficiency syndrome, osteoarthritis, and disseverance osteochondritis in Japan.

To date, we have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents.

The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

### **About StemRIM Inc.**

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called “Regeneration-Inducing Medicine™”. The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. “Regeneration-Inducing Medicine™” is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine

products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

**Inquiries:**

StemRIM Inc.

Management & Administrator Dept.

E-Mail: [stemrim-ir@stemrim.com](mailto:stemrim-ir@stemrim.com)

Twitter: [@StemRIM\\_Inc](https://twitter.com/StemRIM_Inc)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)